期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
^(18)F-FDG PET/CT in differentiating malignant from benign origins of obstructive jaundice 被引量:6
1
作者 Shao-Bo Wang Hu-Bing Wu +4 位作者 Quan-Shi Wang Wen-Lan Zhou Ying Tian Yun-Hai Ji Liang Lv 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS CSCD 2015年第5期516-522,共7页
BACKGROUND: The various origins of obstructive jaundice make the diagnosis of the disease difficult. This study was undertaken to evaluate the role of 18F-FDG PET/CT in differentiating malignant from benign origins o... BACKGROUND: The various origins of obstructive jaundice make the diagnosis of the disease difficult. This study was undertaken to evaluate the role of 18F-FDG PET/CT in differentiating malignant from benign origins of obstructive jaundice and to quantify the added value of 18F-FDG PET/CT over conventional imaging(enhanced CT and/or MRI).METHODS: Eighty-five patients with obstructive jaundice who underwent 18F-FDG PET/CT within 2 weeks after enhanced CT and/or MRI were reviewed retrospectively. All 18F-FDG PET/CT images were independently evaluated by 2 nuclear medicine physicians who were unaware of other imaging data; differences were resolved by consensus of the physicians. All conventional imaging interpretations, according to the medical records, were reviewed by 2 radiologists to determine the potential value. Final diagnoses were based on histological or surgical findings.RESULTS: Sixty-six patients were diagnosed with malignancies, and 19 patients with benign lesions. The maximum standardized uptake values for malignant and benign lesions causing biliary obstruction were 8.2±4.4 and 4.0±5.0, respectively(P〈0.05). The sensitivity, specificity, and overall accuracy for differentiating malignant from benign origins with 18F-FDG PET/CT were 86.4%(57/66), 73.7%(14/19), and 83.5%(71/85), respectively. 18F-FDG PET/CT in conjunction with conventional imaging changed the sensitivity, specificity, and overall accuracy of conventional imaging alone from 75.8%(50/66) to 95.5%(63/66)(P〈0.05), 68.4%(13/19) to 57.9%(11/19)(P〉0.05), and 74.1%(63/85) to 87.1%(74/85)(P〈0.05), respectively.CONCLUSIONS: 18F-FDG PET/CT is of great value in differentiating malignant from benign origins of obstructive jaundice and is a useful adjuvant to conventional imaging. 18F-FDG PET/CT should be recommended for further etiological clarification. 展开更多
关键词 obstructive jaundice fluorodeoxyglucose positron emission tomography/ computed tomography computed tomography magnetic resonance imaging
下载PDF
仑伐替尼联合氟伐他汀对小鼠肝癌移植瘤的抑制作用及其机制 被引量:1
2
作者 雷艺 程旸 +5 位作者 林鑫盛 孙朋辉 康帅 李成 李建聪 朱云 《中国药理学通报》 CAS CSCD 北大核心 2022年第10期1511-1516,共6页
目的探究仑伐替尼联合氟伐他汀对小鼠肝移植瘤的抑制作用及其可能机制。方法构建裸小鼠肝癌皮下移植瘤模型,分别给予氟伐他汀单药、仑伐替尼单药、氟伐他汀联合仑伐替尼和对照溶剂:计算肿瘤倍增时间,免疫组织化学法检测移植瘤组织增殖... 目的探究仑伐替尼联合氟伐他汀对小鼠肝移植瘤的抑制作用及其可能机制。方法构建裸小鼠肝癌皮下移植瘤模型,分别给予氟伐他汀单药、仑伐替尼单药、氟伐他汀联合仑伐替尼和对照溶剂:计算肿瘤倍增时间,免疫组织化学法检测移植瘤组织增殖细胞核抗原(PCNA)的表达水平;TUNEL法检测细胞凋亡水平;实时定量PCR和免疫组织化学法检测TLR4的表达;Western blot法检测β-catenin表达。培养体外肝癌细胞进行Rescue实验,Western blot法检测TLR4及β-catenin表达。结果裸鼠移植瘤实验中,与单药组及对照组相比,联合用药组肿瘤体积最小,肿瘤倍增时间明显延长(P<0.05),PCNA的表达明显降低(P<0.05),细胞凋亡水平明显升高(P<0.05)。联合用药组肝癌组织TLR4的表达较仑伐替尼组明显降低(P<0.05),同时,β-catenin的表达较仑伐替尼组明显降低。体外细胞实验中,过表达TLR4可以逆转氟伐他汀联合仑伐替尼诱导的β-catenin的表达下降。结论与单药仑伐替尼相比,仑伐替尼联合氟伐他汀可明显抑制小鼠肝移植瘤的增殖、促进其凋亡。联合用药可抑制仑伐替尼引起的TRL4及β-catenin的表达升高。联合用药可能是通过抑制TLR4来抑制β-catenin的表达。 展开更多
关键词 仑伐替尼 氟伐他汀 肝细胞癌 增殖 TOLL样受体4 Β-CATENIN
下载PDF
Low glucose metabolism in hepatocellular carcinoma with GPC3 expression 被引量:3
3
作者 You-cai Li chuan-sheng Yang +4 位作者 Wen-Lan Zhou Hong-sheng Li Yan-jiang Han Quan-shi Wang Hu-bing Wu 《World Journal of Gastroenterology》 SCIE CAS 2018年第4期494-503,共10页
AIM To investigate the relationship between glucose metabolism and glypican-3(GPc3)expression in hepatocellular carcinoma(Hcc).METHODSImmunohistochemical staining of pathological samples for GPc3 and glucose transport... AIM To investigate the relationship between glucose metabolism and glypican-3(GPc3)expression in hepatocellular carcinoma(Hcc).METHODSImmunohistochemical staining of pathological samples for GPc3 and glucose transporter 1(GLUT1),and whole-body ^(18)F-FDG PET/c T for measuring tumour glucose uptake were performed in 55 newly diagnosed Hcc patients.The maximum standard uptake value(s UVmax)and tumour-to-non-tumourous liver uptake(T/NT)ratio were used to quantify ^(18)F-FDG uptake.In vitro ^(18)F-FDG uptake assay of GPc3-expressing Hep G2 and non-GPc3-expressing RH7777 cel ls was used to examine the effect of GPc3 in cellular glucose metabolism.The relationships between GPc3 expression and ^(18)F-FDG uptake,GLUT1 expression,tumour differentiation,and other clinical indicators were analysed using spearman rank correlation,univariateand multiple logistic regression analyses.RESULTSPositive GPc3 expression was observed in 67.3%of Hcc patients,including 75.0%of those with well or moderately differentiated Hcc and 36.4%of those with poorly differentiated Hcc.There was an inverse relationship between GPc3 expression and s UVmax(Spearman correlation coefficient=-0.281,P=0.038)and a positive relationship between GLUT1 expression and sU Vmax(Spearman correlation coefficient=0.681,P<0.001)in patients with Hcc.Univariate analysis showed that two glucose metabolic parameters(sU Vmax and T/NT ratio),tumour differentiation,lymph node metastasis,and TNM stage were all significantly associated with GPc3 expression(P<0.05),whereas GLUT1 expression,sex,age,tumour size,intrahepatic lesion number,and distant metastasis showed no statistical association(P>0.05).Further multivariate analysis revealed that only the T/N ratio was significantly correlated with GPC3 expression in patients with Hcc(P<0.05).In vitro assay revealed that the uptake of ^(18)F-FDG in GPc3-expressing HepG2 cells was significantly lower than that of non-GPc3-expressing RH7777 cells(t=-20.352,P<0.001).CONCLUSIONThe present study demonstrated that GPc3 expression is inversely associated with glucose metabolism,suggesting that GPc3 may play a role in regulating glucose metabolism in Hcc. 展开更多
关键词 HEPATOCELLULAR carcinoma GLYPICAN-3 18F-FDG Maximum standard UPTAKE value T/NT ratio GLUCOSE metabolism GLUCOSE TRANSPORTER 1
下载PDF
Positron-emission tomography for hepatocellular carcinoma:Current status and future prospects 被引量:6
4
作者 Ren-Cai Lu Bo She +4 位作者 Wen-Tao Gao Yun-Hai Ji Dong-Dong Xu Quan-Shi Wang Shao-Bo Wang 《World Journal of Gastroenterology》 SCIE CAS 2019年第32期4682-4695,共14页
Hepatocellular carcinoma(HCC)is one of the leading causes of cancer mortality worldwide.Various imaging modalities provide important information about HCC for its clinical management.Since positron-emission tomography... Hepatocellular carcinoma(HCC)is one of the leading causes of cancer mortality worldwide.Various imaging modalities provide important information about HCC for its clinical management.Since positron-emission tomography(PET)or PET-computed tomography was introduced to the oncologic setting,it has played crucial roles in detecting,distinguishing,accurately staging,and evaluating local,residual,and recurrent HCC.PET imaging visualizes tissue metabolic information that is closely associated with treatment.Dynamic PET imaging and dual-tracer have emerged as complementary techniques that aid in various aspects of HCC diagnosis.The advent of new radiotracers and the development of immuno-PET and PET-magnetic resonance imaging have improved the ability to detect lesions and have made great progress in treatment surveillance.The current PET diagnostic capabilities for HCC and the supplementary techniques are reviewed herein. 展开更多
关键词 HEPATOCELLULAR CARCINOMA Positron-emission TOMOGRAPHY Radiotracer Immuno-positron EMISSION TOMOGRAPHY
下载PDF
Preliminary study on the evaluation of Langerhans cell histiocytosis using F-18-fluoro-deoxy-glucose PET/CT 被引量:2
5
作者 Zhou Wenlan Wu Hubing +3 位作者 Han Yanjiang Wang Shaobo Dong Ye Wang Quanshi 《Chinese Medical Journal》 SCIE CAS CSCD 2014年第13期2458-2462,共5页
Background Limited number of studies have been reported regarding the utilization of F-18-fluoro-deoxy-glucose (F-18-FDG) positron emission tomography/computed tomography (F-18-FDG PET/CT) in Langerhans cell histi... Background Limited number of studies have been reported regarding the utilization of F-18-fluoro-deoxy-glucose (F-18-FDG) positron emission tomography/computed tomography (F-18-FDG PET/CT) in Langerhans cell histiocytosis (LCH).The aim of this study was to assess the role of F-18-FDG PET/CT in the diagnosis and treatment of LCH.Methods Eight newly diagnosed and seven recurrent patients with LCH received F-18-FDG PET/CT scans.The diagnosis of LCH was established by pathology,multi-modality imaging,and clinical follow-up.Results F-18-FDG PET/CT was positive in 14 patients with 13 true positives and one false positive.All 45 LCH lesions were F-18-FDG avid including six small bone lesions <1.0 cm in diameter.The mean maximal standardized uptake value (SUVmax) was 7.13±4.91.F-18-FDG uptake showed no significant difference between newly diagnosed lesions vs recurrent lesions (SUVmax:6.50±2.97 vs.7.93±6.60,t=-0.901,P=0.376).Among 45 LCH lesions,68.9% (31/45) were found in bones and 31.1% (14/45) in soft tissue.The most commonly involved bones were the pelvis and vertebrae.There was no significant difference in F-18-FDG uptake between bone lesions vs.non-bone lesions (SUVmax:6.30±2.87 vs.8.97±7.58,t=1.277,P=0.221).In two patients,changes in F-18-FDG uptake on serial PET/CT scans reflected response of lesions to treatment.Conclusions The present study suggests that F-18-FDG PET/CT may be useful for diagnosis and assessing the treatment response of LCH.Because of the small sample size,further research is warranted to confirm our findings. 展开更多
关键词 Langerhans cell histiocytosis diagnosis FOLLOW-UP positron emission tomography computed tomography F-18-FDG
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部